



## BIOINVENT'S CAPITAL MARKETS DAY

### **Highlighting BioInvent's current and planned cancer immunotherapy programs**

You are very welcome to participate in BioInvent's Capital Markets Day on **December 10, 14:00-16:00 at IVA konferenscenter in Stockholm (Grev Turegatan 16).**

On December 10, BioInvent has the pleasure to invite investors, financial analysts and media to attend the Company's Capital Markets Day at the IVA Conference Center, Grev Turegatan 16 in Stockholm between 2 pm and 4 pm. BioInvent has made a concerted effort over the past months to reframe its equity story to better bring out its value drivers – the strength of its discovery platform, the scientific and clinical rationale of targeting Fc gamma receptors in cancer immunotherapy and its leadership in that space, the substantial unmet medical need of the cancer indications it is pursuing, and the associated commercial opportunity.

Speakers at the Capital Markets Day include Martin Welschhof, CEO, Björn Frendéus, Chief Scientific Officer and Andres McAllister, Chief Medical Officer. The presentations will give an overview of BioInvent's current and planned cancer immunotherapy programs, and the company's strategy to create shareholder value. Following the event, a video recording will be published on BioInvent's website.

**To attend the Capital Markets Day, please register by e-mail to [stefan.ericsson@bioinvent.com](mailto:stefan.ericsson@bioinvent.com) or by phone +46 46 286 85 54, no later than December 6.**

For pressrelease and more information click here